Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) Stock Competitors & Peer Comparison

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TAK has a market cap of 57.4B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TAK trades at $18.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TAK's P/E ratio is 12.97. In terms of profitability, ZYBT's ROE is -0.27%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ZYBT is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TAK's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while HLN trades at $10.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas HLN's P/E ratio is 18.85. In terms of profitability, ZYBT's ROE is -0.27%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ZYBT is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HLN's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TEVA has a market cap of 42.4B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TEVA trades at $36.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TEVA's P/E ratio is 12.43. In terms of profitability, ZYBT's ROE is -0.27%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ZYBT is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TEVA's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ZTS trades at $77.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ZTS's P/E ratio is 11.75. In terms of profitability, ZYBT's ROE is -0.27%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ZYBT is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ZTS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while VTRS trades at $16.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas VTRS's P/E ratio is 6.48. In terms of profitability, ZYBT's ROE is -0.27%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ZYBT is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check VTRS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZYBT's ROE is -0.27%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ZYBT is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ITCI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ELAN trades at $24.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ELAN's P/E ratio is 22.76. In terms of profitability, ZYBT's ROE is -0.27%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ZYBT is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ELAN's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZYBT's ROE is -0.27%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ZYBT is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CTLT's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while RDY trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas RDY's P/E ratio is 19.97. In terms of profitability, ZYBT's ROE is -0.27%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ZYBT is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check RDY's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ALKS trades at $47.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ALKS's P/E ratio is 49.91. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ZYBT is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALKS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while LNTH trades at $100.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas LNTH's P/E ratio is 16.94. In terms of profitability, ZYBT's ROE is -0.27%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZYBT is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LNTH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while AMRX trades at $17.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas AMRX's P/E ratio is 19.49. In terms of profitability, ZYBT's ROE is -0.27%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ZYBT is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AMRX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while INDV trades at $34.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas INDV's P/E ratio is 9.55. In terms of profitability, ZYBT's ROE is -0.27%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ZYBT is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check INDV's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ALVOW trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ZYBT is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check ALVOW's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while RGC trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas RGC's P/E ratio is -387.32. In terms of profitability, ZYBT's ROE is -0.27%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ZYBT is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check RGC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SUPN trades at $43.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SUPN's P/E ratio is 14.29. In terms of profitability, ZYBT's ROE is -0.27%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ZYBT is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SUPN's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while BHC trades at $6.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas BHC's P/E ratio is 1.61. In terms of profitability, ZYBT's ROE is -0.27%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ZYBT is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check BHC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZYBT's ROE is -0.27%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ZYBT is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DCPH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while HCM trades at $12.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas HCM's P/E ratio is 4.64. In terms of profitability, ZYBT's ROE is -0.27%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ZYBT is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HCM's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ZYBT's ROE is -0.27%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ZYBT is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AVDL's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TRLV trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TRLV's P/E ratio is -4.80. In terms of profitability, ZYBT's ROE is -0.27%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ZYBT is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check TRLV's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while PRGO trades at $14.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas PRGO's P/E ratio is 5.80. In terms of profitability, ZYBT's ROE is -0.27%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ZYBT is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PRGO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZYBT's ROE is -0.27%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ZYBT is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check EMBCV's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ZYBT's ROE is -0.27%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZYBT is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DVAX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ALVO trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ALVO's P/E ratio is -14.56. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ZYBT is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALVO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ANIP trades at $72.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ANIP's P/E ratio is 8.86. In terms of profitability, ZYBT's ROE is -0.27%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ZYBT is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ANIP's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ETON trades at $59.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ETON's P/E ratio is 129.96. In terms of profitability, ZYBT's ROE is -0.27%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ZYBT is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ETON's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZYBT's ROE is -0.27%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ZYBT is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TARO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while PAHC trades at $37.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas PAHC's P/E ratio is 12.86. In terms of profitability, ZYBT's ROE is -0.27%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ZYBT is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PAHC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while HROW trades at $37.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas HROW's P/E ratio is -37.65. In terms of profitability, ZYBT's ROE is -0.27%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ZYBT is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HROW's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CRON trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CRON's P/E ratio is 32.10. In terms of profitability, ZYBT's ROE is -0.27%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ZYBT is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CRON's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while PCRX trades at $25.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas PCRX's P/E ratio is 9.91. In terms of profitability, ZYBT's ROE is -0.27%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ZYBT is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PCRX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, AMPH has a market cap of 970.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while AMPH trades at $22.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas AMPH's P/E ratio is 7.51. In terms of profitability, ZYBT's ROE is -0.27%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ZYBT is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AMPH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZYBT's ROE is -0.27%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ZYBT is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PETQ's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, COLL has a market cap of 822.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while COLL trades at $25.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas COLL's P/E ratio is 3.18. In terms of profitability, ZYBT's ROE is -0.27%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ZYBT is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check COLL's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, GLAS has a market cap of 768.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while GLAS trades at $9.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas GLAS's P/E ratio is -17.73. In terms of profitability, ZYBT's ROE is -0.27%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ZYBT is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check GLAS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, IRWD has a market cap of 698M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas IRWD's P/E ratio is 5.44. In terms of profitability, ZYBT's ROE is -0.27%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ZYBT is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check IRWD's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, EVO has a market cap of 678.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while EVO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas EVO's P/E ratio is -2.70. In terms of profitability, ZYBT's ROE is -0.27%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ZYBT is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EVO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, AQST has a market cap of 629.8M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while AQST trades at $5.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas AQST's P/E ratio is -7.72. In terms of profitability, ZYBT's ROE is -0.27%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ZYBT is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AQST's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, EOLS has a market cap of 584.8M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while EOLS trades at $8.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas EOLS's P/E ratio is -28.12. In terms of profitability, ZYBT's ROE is -0.27%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ZYBT is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EOLS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZYBT's ROE is -0.27%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZYBT is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check BDSI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TLRY has a market cap of 513.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TLRY trades at $4.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TLRY's P/E ratio is -4.23. In terms of profitability, ZYBT's ROE is -0.27%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ZYBT is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TLRY's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, KMDA has a market cap of 476.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while KMDA trades at $8.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas KMDA's P/E ratio is 21.74. In terms of profitability, ZYBT's ROE is -0.27%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ZYBT is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check KMDA's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CGC has a market cap of 421.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CGC trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CGC's P/E ratio is -0.60. In terms of profitability, ZYBT's ROE is -0.27%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ZYBT is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CGC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TKNO has a market cap of 381.7M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TKNO trades at $7.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TKNO's P/E ratio is -22.97. In terms of profitability, ZYBT's ROE is -0.27%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ZYBT is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TKNO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, EBS has a market cap of 305.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while EBS trades at $5.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas EBS's P/E ratio is 4.11. In terms of profitability, ZYBT's ROE is -0.27%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ZYBT is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EBS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZYBT's ROE is -0.27%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ZYBT is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ALIM's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ZYBT is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LNDC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ACB has a market cap of 248.4M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ACB trades at $4.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ACB's P/E ratio is -8.19. In terms of profitability, ZYBT's ROE is -0.27%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ZYBT is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ACB's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZYBT's ROE is -0.27%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ZYBT is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TYHT's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ORGO has a market cap of 223.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ORGO trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ORGO's P/E ratio is 58.00. In terms of profitability, ZYBT's ROE is -0.27%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ZYBT is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ORGO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CRDL has a market cap of 223.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CRDL trades at $1.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CRDL's P/E ratio is -7.73. In terms of profitability, ZYBT's ROE is -0.27%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ZYBT is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check CRDL's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SIGA has a market cap of 219.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SIGA trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SIGA's P/E ratio is 11.33. In terms of profitability, ZYBT's ROE is -0.27%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ZYBT is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SIGA's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, DERM has a market cap of 205.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while DERM trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas DERM's P/E ratio is -20.19. In terms of profitability, ZYBT's ROE is -0.27%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ZYBT is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DERM's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZYBT is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check REPH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, OGI has a market cap of 171M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while OGI trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas OGI's P/E ratio is 2.73. In terms of profitability, ZYBT's ROE is -0.27%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ZYBT is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check OGI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while LFCR trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas LFCR's P/E ratio is -4.24. In terms of profitability, ZYBT's ROE is -0.27%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ZYBT is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check LFCR's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas THTX's P/E ratio is -28.83. In terms of profitability, ZYBT's ROE is -0.27%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ZYBT is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check THTX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ZYBT's ROE is -0.27%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ZYBT is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ASRT's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CPIX has a market cap of 126.8M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CPIX trades at $8.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CPIX's P/E ratio is -21.15. In terms of profitability, ZYBT's ROE is -0.27%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ZYBT is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CPIX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, BGM has a market cap of 122.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while BGM trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas BGM's P/E ratio is -1.11. In terms of profitability, ZYBT's ROE is -0.27%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ZYBT is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check BGM's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZYBT's ROE is -0.27%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZYBT is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SCTL's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZYBT's ROE is -0.27%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZYBT is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check PROC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZYBT's ROE is -0.27%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ZYBT is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check OPTN's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZYBT's ROE is -0.27%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ZYBT is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ZOM's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZYBT's ROE is -0.27%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ZYBT is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check GRVI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ZYBT's ROE is -0.27%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ZYBT is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ZYNE's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, INCR has a market cap of 68.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while INCR trades at $5.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas INCR's P/E ratio is -13.34. In terms of profitability, ZYBT's ROE is -0.27%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ZYBT is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check INCR's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZYBT's ROE is -0.27%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ZYBT is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SSIC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TLPH trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TLPH's P/E ratio is -3.87. In terms of profitability, ZYBT's ROE is -0.27%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ZYBT is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TLPH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZYBT's ROE is -0.27%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZYBT is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check VLNS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ZYBT's ROE is -0.27%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ZYBT is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check DRRX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZYBT's ROE is -0.27%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ZYBT is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check JUPW's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZYBT's ROE is -0.27%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZYBT is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check QLI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CPHI has a market cap of 36.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CPHI trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CPHI's P/E ratio is -2.10. In terms of profitability, ZYBT's ROE is -0.27%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ZYBT is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CPHI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while RMTI trades at $8.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas RMTI's P/E ratio is -6.10. In terms of profitability, ZYBT's ROE is -0.27%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ZYBT is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check RMTI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZYBT's ROE is -0.27%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZYBT is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check HEXO's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, TXMD has a market cap of 25.7M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while TXMD trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas TXMD's P/E ratio is 113.09. In terms of profitability, ZYBT's ROE is -0.27%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ZYBT is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check TXMD's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while AYTU trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas AYTU's P/E ratio is -1.17. In terms of profitability, ZYBT's ROE is -0.27%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ZYBT is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AYTU's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZYBT's ROE is -0.27%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ZYBT is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CYTH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ZYBT's ROE is -0.27%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ZYBT is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check EVOK's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while OPTH trades at $4.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas OPTH's P/E ratio is -18.08. In terms of profitability, ZYBT's ROE is -0.27%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ZYBT is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check OPTH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZYBT's ROE is -0.27%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ZYBT is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check ACRX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, CABR has a market cap of 12.6M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while CABR trades at $1.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas CABR's P/E ratio is -2.48. In terms of profitability, ZYBT's ROE is -0.27%, compared to CABR's ROE of -3.28%. Regarding short-term risk, ZYBT is more volatile compared to CABR. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check CABR's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZYBT's ROE is -0.27%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ZYBT is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check AGRX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZYBT's ROE is -0.27%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ZYBT is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check NLTX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZYBT's ROE is -0.27%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZYBT is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check LCI's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ZYBT's ROE is -0.27%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ZYBT is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ADMP's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while YCBD trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas YCBD's P/E ratio is -1.25. In terms of profitability, ZYBT's ROE is -0.27%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ZYBT is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check YCBD's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, GELS has a market cap of 5.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while GELS trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas GELS's P/E ratio is -1.11. In terms of profitability, ZYBT's ROE is -0.27%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ZYBT is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check GELS's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas MNK's P/E ratio is -0.44. In terms of profitability, ZYBT's ROE is -0.27%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ZYBT is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check MNK's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ZYBT's ROE is -0.27%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ZYBT is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check FLGC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while UPC trades at $4.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas UPC's P/E ratio is -0.62. In terms of profitability, ZYBT's ROE is -0.27%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ZYBT is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check UPC's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SBFM trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SBFM's P/E ratio is -0.19. In terms of profitability, ZYBT's ROE is -0.27%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ZYBT is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check SBFM's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ZYBT's ROE is -0.27%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ZYBT is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check PLXP's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ZYBT's ROE is -0.27%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ZYBT is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check ATNX's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SNOA trades at $1.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SNOA's P/E ratio is -1.11. In terms of profitability, ZYBT's ROE is -0.27%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, ZYBT is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SNOA's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while SHPH trades at $3.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas SHPH's P/E ratio is -0.17. In terms of profitability, ZYBT's ROE is -0.27%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ZYBT is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for ZYBT.Check SHPH's competition here

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZYBT stands at 82M. In comparison, RDHL has a market cap of 2.1M. Regarding current trading prices, ZYBT is priced at $1.73 on the NASDAQ, while RDHL trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZYBT currently has a P/E ratio of -7.86, whereas RDHL's P/E ratio is 0.13. In terms of profitability, ZYBT's ROE is -0.27%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ZYBT is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ZYBT.Check RDHL's competition here